Low-molecular-weight heparins: Weeks or months instead of days of treatment

Clinical and Applied Thrombosis/Hemostasis

Volumn 7, Issue 4, 2001, Pages 314-320

  Kher, A ^a   Samama, M M ^a  

^a Service d'Hematologie   (France)

Author keywords

Low molecular weight heparin; Pregnancy; Prolonged LMWH treatment; Prolonged thromboprophylaxis; Unstable coronary artery disease

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN, LOW MOLECULAR WEIGHT; LOW MOLECULAR WEIGHT HEPARIN; ANTIVITAMIN K; DALTEPARIN; ENOXAPARIN; NADROPARIN;

CORONARY ARTERY ATHEROSCLEROSIS; FEMALE; HUMAN; MALE; METHODOLOGY; ORTHOPEDICS; PREGNANCY; PREGNANCY COMPLICATION; REVIEW; THROMBOSIS; TIME; ANTICOAGULANT THERAPY; ARTICLE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; LONG TERM CARE; PRIORITY JOURNAL; PROPHYLAXIS; TOTAL HIP PROSTHESIS; VEIN THROMBOSIS;

ANTICOAGULANTS; CORONARY ARTERIOSCLEROSIS; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMAN; MALE; ORTHOPEDICS; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; THROMBOSIS; TIME FACTORS;

EID: 0034774333     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602960100700412     Document Type: Article

References (46)

1. Low-molecular-weight heparin for the treatment of venous thromboembolism
2. Duplex venous scanning for the perspective surveillance of perioperative venous thrombosis
3. Low-dose heparin versus low-molecular-weight heparin (Kabi 2165, Fragmin 1D) in the prophylaxis of thromboembolic complications of abdominal oncological surgery
4. Thrombosis prophylaxis with low-molecular-weight heparin in total hip replacement
5. Failure of low dose heparin to prevent deep vein thrombosis after hip replacement arthroplasty
6. Vascular ultrasonography for deep venous thrombosis after total knee arthroplasty
7. Low-dose heparin and deep vein thrombosis after total hip replacement
8. The natural history and etiology of deep vein thrombosis after total hip replacement
9. Incidence of posthospitalization proximal deep venous thrombosis after total hip arthroplasty
10. Pulmonary embolism and its prophylaxis following the Charnley total hip replacement
11. Postoperative pulmonary embolism after hospital discharge: An underestimated risk
12. The effect of prolonged thromboprophylaxis with dalteparin on the frequency of deep vein thrombosis (DVT) and pulmonary embolism (PE) 35 days after hip replacement surgery (HRS)
13. Risk of deep venous thrombosis after hospital discharge in patients having undergone total hip replacement: Double-blind randomized comparison of enoxaparin versus placebo
14. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement
15. Efficacy and safety of prolonged thromboprophylaxis with a low-molecular-weight heparin (dalteparin) after total hip arthroplasty. The Danish Prolonged Prophylaxis (DaPP) study
16. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital Warfarin/out-of-hospital placebo in hip arthroplasty patients
17. Post discharge clinically overt venous thromboembolism in orthopedic surgery patients with negative venography: An overview analysis
18. Ultrasonographic screening before hospital discharge for deep venous thrombosis after arthroplasty: The post-arthroplasty screening study. A randomized controlled trial
19. The incidence of symptomatic venous thromboembolism during and after prophylaxis with enoxaparin: A multi-institutional cohort study of patients who underwent hip or knee arthroplasty
20. Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip of knee replacement. A randomized, double-blind, placebo-controlled trial
21. Optimal duration of oral anticoagulant therapy in venous thromboembolism
22. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis
23. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis
24. Comparison of subcutaneous unfractionated heparin with a low-molecular-weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin
25. Low-molecular-weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis
26. Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: A randomized trial
27. Low-molecular-weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis
28. Venography comparison of subcutaneous anticoagulant therapy in the long-term treatment of deep venous thrombosis
29. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina
30. Aspirin, sulfinpyrazone, or both in unstable angina
31. Aspirin, sulfinpyrazone, or both in unstable angina
32. Risk of myocardial infarction and death during treatment with low-dose aspirin and intravenous heparin in men with unstable coronary disease
33. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction non-prior aspirin users: Primary end points analysis from the ATACS trial
34. Low-molecular-weight heparin during instability in coronary artery disease
35. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC)
36. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial
37. Long-term low-molecular-mass heparin in unstable coronary artery disease
38. Invasive compared with noninvasive treatment in unstable coronary artery disease
39. Use of low-molecular-weight heparin in pregnancy
40. Low-molecular-weight heparin for obstetric thromboprophylaxis: Experience of sixty-nine pregnancies in sixty-one women of high risk
41. Low-molecular-weight heparin as thromboprophylaxis in pregnancy. A retrospective analysis from 14 European clinics
42. Assessment of a low-molecular-weight heparin (enoxaparin) safety during pregnancy: A retrospective study of 624 pregnancies
43. Safety of low-molecular-weight heparin in pregnancy: A systematic review
44. Thrombosis in pregnancy: Maternal and fetal issues
45. Management of pregnancy in women with thrombophilia
46. Use of antithrombotic agents during pregnancy